M2 Pharma - Policy and Regulations

Gilead Presents Data from Nonalcoholic Steatohepatitis Development Program for Advanced Fibrosis

13 November 2018 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has presented new data from the company's clinical development programme for advanced fibrosis due to ...

Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting 2018

13 November 2018 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has presented results from studies investigating Epclusa (sofosbuvir 400mg/velpatasvir 100mg) in chron...

Alnylam Presents Updated Phase 1/2 Open-Label Extension Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

13 November 2018 - - US-based RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading, announced TODAY that the company presented updated results from the ongoing Phas...

Nocdurna Sublingual Tablets Now Available by Prescription in US for Treatment of Nocturia Due to Nocturnal Polyuria

13 November 2018 - - Swiss specialty biopharmaceutical group Ferring Pharmaceuticals Inc. has launched Nocdurna (desmopressin acetate), the first and only sublingual tablet approved in the United...

Global Cervical Cancer Diagnostic Testing Market to Grow at a CAGR of Over 6% by 2023, According to Technavio

13 November 2018 - - Analysts at UK-based technology research and advisory company Technavio forecast the global cervical cancer diagnostic testing market to grow at a CAGR of over 6% durin...

New Data from Investigational Study of Lenvima and Keytruda Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd annual meeting

13 November 2018 - - Japanese drugmaker Eisai Co., Ltd. and US-based Merck (NYSE: MRK) have received results from presentations of new data and analyses of Lenvima (lenvatinib), an orally available ki...